Telehealth weight management · Provider sources reviewed

Henry Meds: weight-loss provider profile

Henry’s current site describes provider-led weight-management treatment and compounded-medication limitations. Old fixed prices and delivery ratings are no longer presented as verified facts.

Sources checked October 2, 2026 · Medical review pending

Written by the My Chubby Journey editorial team with AI assistance. This is a commercial affiliate site. Earlier “Sarah” stories were fictional; this page presents research, not a patient testimonial. How we research · Commercial disclosure.

Current findings for Henry Meds

Painted illustration of a blank weekly planner, phone, pen and glass of water on a desk.
AI-generated editorial illustration.

Current treatment information

Henry’s semaglutide page describes a clinical evaluation and treatment if appropriate. Its FAQ explains that compounded medicines are custom preparations and are not reviewed by FDA for safety or efficacy. The older site’s universal price and hands-on service assessment were not independently verified.

Clinical review before purchase

The provider advertises a no-obligation evaluation on its semaglutide page. Ask when payment begins, whether your final dose or formulation changes the price and which pharmacy would supply it. Clinical eligibility is separate from completing an intake.

Understand the medication before comparing providers

Approved weight-management options include Wegovy (semaglutide), Zepbound (tirzepatide) and Foundayo (orforglipron), each with its own indication, formulation and instructions. Ozempic and Mounjaro are diabetes brands. The current provider findings above identify what could be verified about this company; this general comparison does not establish that it offers every named medicine.

Wegovy has injectable and oral formulations, Zepbound is injectable, and Foundayo is oral. A compounded or dissolvable product is not the approved branded product. Identify the exact prescription and route before comparing price or applying a trial result.

Compounded medicines are not FDA-approved. FDA recommends them only when a patient’s medical needs cannot be met by an approved medicine. Its April 2026 update says semaglutide and tirzepatide are not on the drug shortage list or the 503B bulks list. Patient-specific exceptions and other legal conditions matter; a “personalized” label, vitamin additive, or pharmacy registration does not by itself establish compliance or effectiveness.

Safety questions for the prescribing clinician

The approved products cited here have a boxed warning about thyroid C-cell tumors in rodents; whether they cause these tumors in humans is unknown. Their contraindications include a personal or family history of medullary thyroid carcinoma (MTC), MEN 2, and specified serious allergic reactions. These are specific conditions, rather than a statement that every thyroid disorder rules out treatment. Review the exact product label with your clinician.

Tell the clinician about severe stomach-emptying problems, pancreatitis or gallbladder history, kidney concerns, diabetic eye disease, and every medicine or supplement you use. The labels do not recommend these products in severe gastroparesis. Insulin and medicines such as sulfonylureas can increase low-blood-sugar risk when used with them; adjustments belong with the prescriber. These examples do not replace the full safety review.

For weight management, Wegovy should be discontinued when pregnancy is recognized, and its label calls for stopping at least two months before a planned pregnancy. Ozempic also specifies at least two months before a planned pregnancy. Discuss the plan before trying to conceive. Wegovy tablets are not recommended during breastfeeding; the injection requires its own benefit-and-risk discussion.

Zepbound should be discontinued when pregnancy is recognized. Tirzepatide can reduce the effectiveness of oral hormonal contraceptives: the Zepbound and Mounjaro labels advise a non-oral method or an added barrier method for four weeks after starting and for four weeks after each dose increase. Ask the clinician about pregnancy planning and breastfeeding for the exact prescription.

Foundayo also calls for discontinuation when pregnancy is recognized. Its oral-contraceptive precautions use 30 days after starting and 30 days after each dose increase. It is not recommended for nursing women. Do not substitute one product’s contraception or pregnancy instructions for another’s.

Severe abdominal pain that does not go away, with or without vomiting, can be a pancreatitis warning; the labels instruct patients to stop the medicine and seek medical help promptly. Repeated vomiting or inability to keep fluids down also needs prompt assessment. For trouble breathing or swallowing, swelling of the face, tongue or throat, or collapse suggesting a serious allergic reaction, call 911 or your local emergency number immediately. Your provider should explain urgent and after-hours care before treatment starts.

Tell the anesthesia or procedure team about treatment before surgery or deep sedation. Do not independently combine GLP-1 products, shorten injection intervals or restart an old high dose after a break. Procedure planning and side effects and warning symptoms explain the questions to resolve with the care team.

Questions to resolve before paying Henry Meds

  • Which exact medication and formulation would my prescription specify, and which pharmacy would dispense it?
  • What are the total first and renewal payments, and does the advertised monthly price require prepayment?
  • Who manages side effects and dose changes, and what follow-up care is included?
  • What is the cancellation deadline, and which fees remain non-refundable?

Ask for a written quote showing the medication, care or membership fee, labs, shipping, supplies, first payment, renewal payment, and cancellation cutoff. A monthly equivalent on a prepaid plan is different from paying that amount every month. A four-week supply and a calendar-month subscription also have different annual totals.

Verify your prescriber’s license and the dispensing pharmacy with the relevant state boards. Check that the pharmacy named on your prescription matches the pharmacy on the package. If injectable medication arrives warm or inadequately refrigerated, FDA advises against using it; contact the dispensing pharmacy for instructions. Avoid products sold as research chemicals or without a prescription.

How to use this profile

This is a review of public information, not a hands-on clinical test or a verified patient review. We do not assign star ratings to clinical care, medication quality, response time, or shipping. An advertised benefit remains a provider claim unless independent evidence supports the specific claim. Confirm current availability, state eligibility, and the final terms directly before enrolling.

Read our source and correction policy and commercial disclosure. Medical review has not been completed.

Sources and verification

Provider pages document what a company advertises. Prescribing information and regulator guidance support medical and regulatory claims. Reviewing a website does not verify its clinical service, pharmacy quality, or your eligibility.

  1. Semaglutide for Weight Loss | Henry
    provider · Text reviewed · Checked October 2, 2026
  2. FAQ | Henry
    provider · Text reviewed · Checked October 2, 2026
  3. Henry | Personalized Weight Loss, Hormone & Sexual Health Care
    provider · Text reviewed · Checked October 2, 2026
  4. Wegovy prescribing information
    prescribing information · Text reviewed · Checked October 2, 2026
  5. Ozempic prescribing information
    prescribing information · Text reviewed · Checked October 2, 2026
  6. Zepbound prescribing information
    prescribing information · Text reviewed · Checked October 2, 2026
  7. Mounjaro prescribing information
    prescribing information · Text reviewed · Checked October 2, 2026
  8. Foundayo prescribing information
    prescribing information · Text reviewed · Checked October 2, 2026
  9. Anaphylaxis: MedlinePlus Medical Encyclopedia
    clinical guidance · Text reviewed · Checked October 2, 2026
  10. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA
    regulator · Text reviewed · Checked October 2, 2026
  11. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA
    regulator · Text reviewed · Checked October 2, 2026